Using continuous glucose monitoring after childbirth for women with diabetes
Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes
This study tests if using continuous glucose monitoring after childbirth can help women with type 1 and type 2 diabetes catch low blood sugar episodes better than regular glucose testing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT06141941 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of continuous glucose monitoring (CGM) compared to traditional glucose testing in identifying hypoglycemic episodes in women with type 1 and type 2 diabetes during the immediate postpartum period. Participants will have a CGM device placed upon admission to the hospital, and their glucose data will be monitored by nursing staff through a dedicated app. The study aims to enhance patient safety by providing real-time glucose data and alerts for hypoglycemia. The approach involves both the use of personal devices and hospital-provided technology to ensure comprehensive monitoring.
Who should consider this trial
Good fit: Ideal candidates are women in their third trimester of pregnancy with type 1 or type 2 diabetes who are admitted to the hospital.
Not a fit: Patients under 18 years old, non-English speakers, those with gestational diabetes, or individuals with skin conditions that prevent sensor use may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of hypoglycemic episodes in postpartum women with pregestational diabetes.
How similar studies have performed: Other studies have shown promise in using continuous glucose monitoring for diabetes management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: 1- Individuals in the third trimester of pregnancy admitted to the hospital with diabetes type 1 or diabetes type 2, own a smart device (which will serve as a receiver for the CGM device) Exclusion: 1. Patients less than 18 years of age 2. non-English speaking patients 3. gestational diabetes 4. extensive skin changes/diseases that inhibit wearing a sensor on normal skin, known allergy to adhesives
Where this trial is running
Iowa City, Iowa
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Principal investigator: Andrea Greiner, MD — University of Iowa OBGYN
- Study coordinator: Andrea Greiner, MD
- Email: andrea-greiner@uiowa.edu
- Phone: +1 319 356 3180
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.